TY - JOUR
T1 - TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories
AU - Land, Sally
AU - Cunningham, Philip
AU - Zhou, Jialun
AU - Frost, Kevin
AU - Katzenstein, David
AU - Kantor, Rami
AU - Chen, Yi Ming Arthur
AU - Oka, Shinichi
AU - DeLong, Allison
AU - Sayer, David
AU - Smith, Jeffery
AU - Dax, Elizabeth M.
AU - Law, Matthew
N1 - Funding Information:
The TREAT Asia Quality Assurance Scheme is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, and is supported in part by amfAR with additional support from the Dutch Ministry of Foreign Affairs through a partnership with Stichting Aids Fonds. The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine of The University of New South Wales. The content of this publication is, however, solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. The TAQAS Laboratory Network: L. Kang, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China; W.C. Yam and J. Chen, HIV Molecular Biology Laboratory, Department of Microbiology, Queen Mary Hospital, Hong Kong; S. Oka and X. Bi, AIDS Clinical Center, International Medical Center of Japan, Tokyo, Japan; W. Sugiura, National Institute of Infectious Diseases, Tokyo, Japan; N. Kumarasamy, V. Madhavan and S. Saravanan, Infectious Diseases Laboratory, Chennai, India; K.P. Ng and A. Kamarulzaman, HIV Research Laboratory, Medical Microbiology Department, University of Malaya, Kuala Lumpur, Malaysia; W. Stevens and C. Wallis, National Health Laboratory Services (NHLS)—University of Witwatersrand, Johannesburg, S. Africa; Y.M.A. Chen and Y.J. Chen, AIDS Centre of the National Yang-Ming University, Taipei, Taiwan; R. Sutthent, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand; K. Ruxrungtham and S. Sirivichayakul, Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; W. Chantratita, W. Piroj and C. Watitpun, Virology and Molecular Microbiology Unit, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; M. Winters, D. Katzenstein and M. Balamane, Center for AIDS Research, Division of Infectious Diseases and Geographic Medicine, Stanford University, CA, USA; T.T.X. Lien and T.C. Thanh, HIV/AIDS laboratory, Pasteur Institute in Hochiminh City, Ho Chi Minh City, Vietnam.
PY - 2009/8/1
Y1 - 2009/8/1
N2 - The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.
AB - The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p < 0.01). Interpretation of antiretroviral resistance showed ∼70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.
KW - Drug resistance
KW - Genotyping
KW - HIV
KW - Quality assessment
KW - TAQAS
UR - http://www.scopus.com/inward/record.url?scp=67349098439&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349098439&partnerID=8YFLogxK
U2 - 10.1016/j.jviromet.2009.03.016
DO - 10.1016/j.jviromet.2009.03.016
M3 - Article
C2 - 19490972
AN - SCOPUS:67349098439
SN - 0166-0934
VL - 159
SP - 185
EP - 193
JO - Journal of Virological Methods
JF - Journal of Virological Methods
IS - 2
ER -